KAMIREN Prolonged-release tablet Ref.[49837] Active ingredients: Doxazosin

Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Product name and form

Kamiren 4 mg prolonged-release tablets.

Pharmaceutical Form
Prolonged-release tablets. Kamiren 4 mg prolonged-release tablets are white, round, biconvex tablets.

Qualitative and quantitative composition

Each tablet contains 4mg doxazosin (as mesilate).

Excipient(s) with known effect: Lactose Monohydrate 74.27mg.

For the full list of excipients, see section 6.1.

Active Ingredient	Description
Doxazosin	Doxazosin is a potent and selective post-junctional alpha-1-adrenoceptor antagonist. This action results in a decrease in systemic blood pressure.

List of Excipients
Tablet core: Hypromellose Calcium hydrogen phosphate Lactose monohydrate Magnesium stearate Coating: Opadry white Y-1-7000 consists of: Hypromellose Titanium dioxide (E171) Macrogol 400

Pack sizes and marketing

Kamiren 4 mg prolonged-release tablets are available as pack of 28 tablets.

OPA/Alu/PVC film with Alu foil blister strips in a carton box.

Marketing authorization holder

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Marketing authorization dates and numbers

PA1347/038/001

Date of first authorisation: 3^rd March 2006
Date of last renewal: 3^rd March 2011

Drugs

Drug	Countries
KAMIREN	Estonia, Hong Kong, Croatia, Ireland, Lithuania, Poland, Romania

Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.